Literature DB >> 21707704

Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer.

Martin Braun1, Veit J Scheble, Roopika Menon, Gregor Scharf, Theresia Wilbertz, Karen Petersen, Christine Beschorner, Markus Reischl, Rainer Kuefer, David Schilling, Arnulf Stenzl, Glen Kristiansen, Mark A Rubin, Falko Fend, Sven Perner.   

Abstract

AIMS: ERG rearrangements, mostly resulting in TMPRSS2-ERG fusions, are frequent alterations in prostate cancer (PCa), with a frequency ranging from 15% to 78%. As the reason for this variability is unknown, our aim was to investigate the ERG rearrangement frequency with a cohort design. METHODS AND
RESULTS: We assessed three well-defined cohorts for ERG rearrangements, using fluorescence in situ hybridization (FISH). The first cohort comprised 119 prostatectomy specimens. The second and third cohorts included incidentally diagnosed PCa [71 cystoprostatectomy specimens, and 105 transurethral resection of the prostate (TURP) specimens]. Seventy of 119 (59%) cases of the prostatectomy cohort harboured ERG rearrangements. Regarding zonal origin, 2/11 (18%) transition zone (TZ) foci and 75/145 (52%) peripheral zone (PZ) foci harboured ERG rearrangements. Within the cystoprostatectomies, 24/71 (34%) cases harboured ERG rearrangements. Regarding zonal origin, 2/9 (22%) TZ foci and 26/86 (30%) PZ foci harboured ERG rearrangements. PCa incidentally identified by TURP harboured ERG rearrangements in 31/105 (29%) cases.
CONCLUSIONS: ERG rearrangements occur in TZ PCa, although at a lower frequency than in PZ PCa. We confirmed that approximately half of all prostatectomies harbour ERG rearrangements. However, the frequency in incidentally diagnosed PCa cohorts was significantly lower, even if multifocality was considered. Consequently, zonal origin and cohort design are key for studying the clinical implications of ERG rearrangements.
© 2011 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21707704     DOI: 10.1111/j.1365-2559.2011.03862.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  13 in total

1.  Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.

Authors:  Ramy A Abdelsalam; Ibrahim Khalifeh; Alan Box; Maria Kalantarian; Sunita Ghosh; Hatem Abou-Ouf; Tamara Lotfi; Mohammed Shahait; Nallasivam Palanisamy; Tarek A Bismar
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-30       Impact factor: 4.553

Review 2.  TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.

Authors:  Cindy Ke Zhou; Denise Young; Edward D Yeboah; Sally B Coburn; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Shelley Niwa; Ann Truelove; Judith Welsh; James E Mensah; Robert N Hoover; Isabell A Sesterhenn; Ann W Hsing; Shiv Srivastava; Michael B Cook
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

3.  The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.

Authors:  Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

Review 4.  [Dangerous liaisons in prostate cancer. Clinical and biological implications of recurrent gene fusions].

Authors:  S Perner
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

5.  TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.

Authors:  Anuradha Gopalan; Margaret A Leversha; Maria E Dudas; Alexandra C Maschino; Jeremy Chang; Hikmat A Al-Ahmadie; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter; Samson W Fine
Journal:  Histopathology       Date:  2013-05-23       Impact factor: 5.087

6.  ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer.

Authors:  Veit J Scheble; Gregor Scharf; Martin Braun; Christian Ruiz; Susanna Stürm; Karen Petersen; Rudi Beschorner; Alexander Bachmann; Tobias Zellweger; Falko Fend; Glen Kristiansen; Lukas Bubendorf; Nicolas Wernert; David Adler; Sven Perner
Journal:  Virchows Arch       Date:  2012-07-06       Impact factor: 4.064

7.  Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studies.

Authors:  F Huber; M Montani; T Sulser; R Jaggi; P Wild; H Moch; H Gevensleben; M Schmid; S Wyder; G Kristiansen
Journal:  Br J Cancer       Date:  2014-11-25       Impact factor: 7.640

8.  HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.

Authors:  Steven C Smith; Nallasivam Palanisamy; Kimberly A Zuhlke; Anna M Johnson; Javed Siddiqui; Arul M Chinnaiyan; Lakshmi P Kunju; Kathleen A Cooney; Scott A Tomlins
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

9.  ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer.

Authors:  David Adler; Jacqueline Ochsenfahrt; Kerstin Fuchs; Glen Kristiansen; Sven Perner; Nicolas Wernert
Journal:  Int J Mol Med       Date:  2012-08-20       Impact factor: 4.101

10.  Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors.

Authors:  Niklas Klümper; Isabella Syring; Sven Perner; Felix Bremmer; Anne Offermann; David Adler; Wenzel Vogel; Stefan C Müller; Jörg Ellinger; Arne Strauß; Heinz Joachim Radzun; Philipp Ströbel; Johannes Brägelmann
Journal:  Diagn Pathol       Date:  2015-09-17       Impact factor: 3.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.